• CNBX Pharmaceuticals posted a net loss of USD 154,165 for the three months ended May 31, 2026, widening from USD 59,727 a year earlier.
• Operating expenses more than doubled to USD 162,763, driven by higher general and administrative costs.
• Financial results swung to income of USD 8,598 from a loss of USD 19,347, mainly due to interest on convertible loans.
• Cash fell to USD 9,487 as of May 31, 2026 from USD 15,111 at Aug. 31, 2025; it expects at least USD 1 million of expenses over 12 months.
• CNBX reiterated it aims to start first-in-human Phase I/II trials for colorectal cancer candidate RCC-33 in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNBX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005078), on June 24, 2026, and is solely responsible for the information contained therein.